Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d'Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM).
Ianotto JC, Kiladjian JJ, Demory JL, Roy L, Boyer F, Rey J, Dupriez B, Berthou C, Abgrall JF. Ianotto JC, et al. Among authors: abgrall jf. Br J Haematol. 2009 Jul;146(2):223-5. doi: 10.1111/j.1365-2141.2009.07745.x. Epub 2009 May 26. Br J Haematol. 2009. PMID: 19545286 Free article. No abstract available.
Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.
Ianotto JC, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, De Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Schoenwald M, Andreoli A, Abgrall JF, Kiladjian JJ. Ianotto JC, et al. Among authors: abgrall jf. Br J Haematol. 2013 Sep;162(6):783-91. doi: 10.1111/bjh.12459. Epub 2013 Jul 13. Br J Haematol. 2013. PMID: 23848933 Free article.
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ; FOX study investigators. Rey J, et al. Eur J Haematol. 2014 Feb;92(2):127-36. doi: 10.1111/ejh.12210. Epub 2013 Nov 25. Eur J Haematol. 2014. PMID: 24118452 Free PMC article. Clinical Trial.
Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
Abgrall JF, Guibaud I, Bastie JN, Flesch M, Rossi JF, Lacotte-Thierry L, Boyer F, Casassus P, Slama B, Berthou C, Rodon P, Leporrier M, Villemagne B, Himberlin C, Ghomari K, Larosa F, Rollot F, Dugay J, Allard C, Maigre M, Isnard F, Zerbib R, Cauvin JM; Groupe Ouest-Est Leucémies et Maladies du Sang (GOELAMS). Abgrall JF, et al. Haematologica. 2006 Aug;91(8):1027-32. Haematologica. 2006. PMID: 16885042 Clinical Trial.
[Ofuji's papuloerythroderma: efficacy of interferon-alpha].
Plantin P, Milochau P, Leroy JP, Berthou C, Sensebe L, Abgrall JF, Guillet G. Plantin P, et al. Among authors: abgrall jf. Ann Dermatol Venereol. 1992;119(9):643-5. Ann Dermatol Venereol. 1992. PMID: 1285589 Review. French. No abstract available.
Evaluation of chromosome 5 aberrations in complex karyotypes of patients with myeloid disorders reveals their contribution to dicentric and tricentric chromosomes, resulting in the loss of critical 5q regions.
Herry A, Douet-Guilbert N, Morel F, Le Bris MJ, Morice P, Abgrall JF, Berthou C, De Braekeleer M. Herry A, et al. Among authors: abgrall jf. Cancer Genet Cytogenet. 2007 Jun;175(2):125-31. doi: 10.1016/j.cancergencyto.2007.02.008. Cancer Genet Cytogenet. 2007. PMID: 17556068
127 results